Norrby A, Sölvell L
Scand J Haematol Suppl. 1977;32:270-6. doi: 10.1111/j.1600-0609.1977.tb01250.x.
Ferastral, a new iron-poly (sorbitol-gluconic acid) complex for parenteral use has been given to 22 patients with iron deficiency anaemia. The patients were divided in two groups. Group I received a suboptimal dose of Ferastral iron corresponding to 90% of the iron calculated to normalize the haemoglobin value. Increases in total haemoglobin and also blood losses were measured. The availability of the injected iron for haemoglobin synthesis ranged from 63% to 111%. Group II received an amount of Ferastral-iron calculated to be necessary for normalization of the haemoglobin plus an additional 500 mg of Ferastral-iron. In this group the haemoglobin increase was rapid. In 7 weeks 10 out of 14 patients had reached a normal haemoglobin level.
费拉斯托(Ferastral)是一种新的供肠胃外使用的铁-聚(山梨醇-葡萄糖酸)复合物,已用于22例缺铁性贫血患者。患者被分为两组。第一组接受低于最佳剂量的费拉斯托铁,其剂量相当于计算得出的使血红蛋白值正常化所需铁量的90%。测量了总血红蛋白的增加量以及失血量。注射铁用于血红蛋白合成的利用率在63%至111%之间。第二组接受的费拉斯托铁量经计算是使血红蛋白正常化所需的量再额外加上500毫克费拉斯托铁。在这组中,血红蛋白快速上升。14名患者中有10名在7周内血红蛋白水平达到正常。